Extendin derivatives
The present invention relates to novel derivatives of exendin-4 or exendin-4 fragments, wherein the derivatives have a lipophilic substituent attached, optionally via a spacer, to an amino acid residue, which is not the N-terminal or C-terminal amino acid residue of the derivative.
1. A derivative of exendin-4 or a fragment thereof, wherein said derivative has one lipophilic substituent attached, optionally via a spacer, to an amino acid residue of said exendin-4 or fragment thereof, which is not the N-terminal or C-terminal amino acid residue of said exendin-4 or fragment thereof, wherein said fragment has insulinotropic activity.
2. A pharmaceutical composition comprising a derivative of claim 1 and a pharmaceutically acceptable vehicle or carrier.
3. A method of treating insulin dependent or non-insulin dependent diabetes mellitus in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a derivative of claim 1 and a pharmaceutically acceptable carrier.
4. The derivative of claim 1 , wherein the lipophilic substituent has 4 to 40 carbon atoms.
5. The derivative of claim 4 , wherein the lipophilic substituent has 8 to 25 carbon atoms.
6. The derivative of claim 4 , wherein the lipophilic substituent is attached by means of a spacer.
7. The derivative of claim 6 , wherein the spacer is an unbranched alkane α,ω-dicarboxylic acid group having from 1 to 7 methylene groups.
8. The derivative of claim 4 , wherein the lipophilic substituent is a straight-chain or branched acyl group.
9. The derivative of claim 8 , wherein the acyl group is of the formula CH 3 (CH 2 ) n CO—, wherein n is 4 to 38.
10. The derivative of claim 9 , wherein the acyl group is CH 3 (CH 2 ) 6 CO—, CH 3 (CH 2 ) 8 CO—, CH 3 (CH 2 ) 10 CO—, CH 3 (CH 2 ) 12 CO—, CH 3 (CH 2 ) 14 CO—, CH 3 (CH 2 ) 16 CO—, CH 3 (CH 2 ) 18 CO—, CH 3 (CH 2 ) 20 CO— or CH 3 (CH 2 ) 22 CO—.